Answers are grounded in this paper and cite their sources.
Prospective analysis reveals high-grade disease prevalence in reproductive-age women with high-risk hpv, emphasizing the need for thorough assessment.
Background: Persistent infection with high-risk human papillomavirus (HR‑HPV) is the necessary cause of the vast majority of cervical cancers and the driver of cervical intraepithelial neoplasia (CIN).1 Fourteen genotypes are considered oncogenic, with HPV16 and HPV18 accounting for the largest share of the global cervical cancer burden.2 While the cervix has been the focus of screening and prevention for decades, the anal canal – lined by a vulnerable transformation zone analogous to the cervix – can also harbor HR‑HPV, develop anal intraepithelial neoplasia (AIN), and progress to squamous cell carcinoma.3 Anal cancer incidence has risen in many settings, and women constitute a growing proportion of cases.4Despite these parallels, routine gynecologic care rarely includes anal assessment.5 The natural history of anal HPV infection in immunocompetent, HIV‑negative women with cervical disease remains poorly characterized, and evidence regarding concurrent high‑grade disease at both sites is limited.6 A more precise estimate of the prevalence of AIN 2/3 among women with CIN 2/3, coupled with HPV genotype concordance data, could inform whether targeted anal evaluation should be integrated into follow‑up.7 Addressing this knowledge gap is particularly important in regions where cervical screening is established but anal screening is not standard of care.
No takes yet. Share an insight, caveat, or question.
Museridze et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: